MRC1 and colorectal carcinoma: Approximately 15% of CRC tumors have deficiencies in the MMR pathway, a feature that affects long-term prognosis and sensitivity to certain chemotherapies and immune checkpoint inhibitors [30,31,32,33,34,35].